GILEAD SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.76 USD | +0.75% |
|
-1.89% | -19.15% |
| 04:49pm | TD Cowen Adjusts Price Target on Gilead Sciences to $85 From $90 | MT |
| 04:23pm | Jefferies Adjusts Gilead Sciences' Price Target to $80 From $95 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
2024-05-08
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.27
USD
Average target price
84.22
USD
Spread / Average Target
+29.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.15% | 81.39B | |
| +26.11% | 653B | |
| +27.00% | 556B | |
| -6.47% | 354B | |
| +20.14% | 331B | |
| +3.85% | 296B | |
| +12.88% | 233B | |
| +5.59% | 201B | |
| -9.65% | 193B | |
| -6.30% | 144B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Earnings Flash (GILD) GILEAD SCIENCES Reports Q2 Revenue $6.26B
